Emendo Biotherapeutics vs FORE Biotherapeutics
Emendo Biotherapeutics vs FORE Biotherapeutics, compared side by side on 21 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Emendo Biotherapeutics is on 59/100 and FORE Biotherapeutics on 56/100.
Where each one leads
Emendo Biotherapeutics
- our overall score: 59/100 against 56/100
FORE Biotherapeutics
- domain rating: 33/100 against 20/100
- headcount: 56 against 41
- headcount growth: +8.2% against -16.1%
- funding raised: $232M against $61.0M
At a glance
| Measure | Emendo Biotherapeutics | FORE Biotherapeutics |
|---|---|---|
| What it is | Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology. | Precision oncology company developing cancer therapies guided by proprietary functional genomics. |
| Category | Healthcare, Genome Editing, CRISPR, Biotech | Healthcare, Drug Development, Genomics, Next Generation Sequencing |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Software |
| Founded | 2015 | 2011 |
| Headquarters | Tel Aviv, Israel | Philadelphia, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | Emendo Biotherapeutics | FORE Biotherapeutics |
|---|---|---|
| Employees | 41 | 56 |
| Headcount growthLast 12 months | -16.1% | +8.2% |
| Total funding | $61.0M | $232M |
| Latest round | Series B | Series D-2 Extension |
| Valuation | Not published | $75.0M |
| LinkedIn followers | 5,333 | 4,584 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Emendo Biotherapeutics | FORE Biotherapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 59/100 | 56/100 |
| Traction | 55/100 | 58/100 |
| Team | 40/100 | 70/100 |
| Search visibility | 44/100 | 38/100 |
| Quality | 68/100 | 55/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (40/100) | F (37/100) |
| Domain ratingLink authority, 0-100 | 20/100 | 33/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Emendo Biotherapeutics | FORE Biotherapeutics |
|---|---|---|
| Hosting | Google Cloud | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Bootstrap | Jquery |
| Analytics | Google Tag Manager | Not detected |
Emendo Biotherapeutics vs FORE Biotherapeutics: common questions
Which is better, Emendo Biotherapeutics or FORE Biotherapeutics?
On our 0-100 score Emendo Biotherapeutics rates higher (59/100 against 56/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 21 data points above: read the rows that match what you are buying for.
How do Emendo Biotherapeutics and FORE Biotherapeutics compare on the numbers?
Emendo Biotherapeutics leads on our overall score (59/100 against 56/100). FORE Biotherapeutics leads on domain rating (33/100 against 20/100), headcount (56 against 41), headcount growth (+8.2% against -16.1%), funding raised ($232M against $61.0M).
Read the full Emendo Biotherapeutics review and pricing or the FORE Biotherapeutics review and pricing. You can also browse other Emendo Biotherapeutics alternatives we track.